Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Despite Breakthroughs, No Hurry To Venture Into The Microbiome

This article was originally published in Start Up

Executive Summary

A few start-ups and their backers have begun to pursue therapeutics for diseases modulated by our commensal, or beneficial, microbial populations. But the science is too new, and the VC world too shaken, to spur a rush to invest.

You may also be interested in...



Flagship Ventures Dives Into Microbiome, Launches Seres Health

Only a few biopharmaceutical start-ups have formed in the emerging microbiome space, but VC firm Flagship says its homegrown Seres Health, still somewhat stealthy, is developing a new category of drugs that aim to rebalance microbiome populations causing disease.

NuMe Health Inc.

NuMe Health Inc. aims to market mixtures of edible substances that will act as "prebiotics" to shift ratios of certain bacteria in the lower intestine. The start-up intends to educate consumers about how "managing the microbiome" with products that are not drugs can positively affect metabolic health. First up: a mixture NuMe expects will improve biomarkers associated with pre-diabetes.

AAVLife: Another Gene Therapy Effort To Treat Friedreich's Ataxia

With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC092337

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel